{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"PancChat Podcast with Alisyn Camerota","title":"Rasonque™: A New Drug for Pancreatic Cancer","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/9bd3fbb0\"></iframe>","width":"100%","height":180,"duration":1506,"description":"The U.S. Food & Drug Administration (FDA) just approved a treatment that doubled survival time for patients with metastatic pancreatic cancer — what does this landmark approval mean for you or a loved one?\n\nTo get the latest information, host Alisyn Camerota is joined by Dr. Brian Wolpin, a medical oncologist at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School.\nDr. Wolpin breaks down what the FDA's approval of Rasonque™ (daraxonrasib) means for patients, how the drug works differently from chemotherapy, who's eligible to receive it, what side effects look like and how they're managed, and what's next as researchers explore other types of RAS inhibitors, novel combinations, different stages of disease, and more.\n\nPancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN. \n\nThanks to our sponsor, Revolution Medicines.\nResources:\nFDA Approves RASONQUE™ (daraxonrasib) - PanCAN\nThe FDA Approves Rasonque™ (Daraxonrasib) - Let's Win\nDaraxonrasib: What To Know About Common Side Effects\nLet's Win Pancreatic Cancer\nPancreatic Cancer Action Network (PanCAN)\nLet's Win Clinical Trial Finder\nPanCAN Clinical Trial Finder\nLet's Win Doctor Finder \nPanCAN Patient Services ","thumbnail_url":"https://img.transistorcdn.com/cAJEAPlDE1maKBGcgHeLPBFdNegZ6bz0Ol0rS-Dsvj0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mZThh/MzliZmRmOThiY2U5/ZGNlNWI0MGE2Mjdj/NDkzMy5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}